Advancing precision oncology with spatial biomarkers: A novel multiplex imaging and AI-powered workflow
Session OneMonday, 15 December 2025, 2 a.m. Eastern (ET), 8 a.m. Central Europe (CET), 12:30 p.m. (IST) , 3 p.m. (CST/HKT/SGT), 4 p.m. (JST/KST)
Session TwoMonday, 15 December 2025, 12 p.m. Eastern (ET), 6 p.m. Central Europe (CET), 10:30 p.m. (IST) , 1 a.m. (CST/HKT/SGT), 2 a.m. (JST/KST)
The promise of precision oncology lies in understanding not only what biomarkers are present in a tumor, but where they are—and how their spatial relationships influence treatment response. In a groundbreaking study, researchers used multiplex imaging and AI-driven spatial analysis to reveal, for the first time, how melanoma patients respond to immunotherapy, identifying predictive spatial biomarkers that correlate with outcomes.
This webinar will bring together experts in immuno-oncology, digital pathology, and clinical oncology to discuss how spatial biology and advanced image analysis are transforming cancer research and care. Speakers will highlight how a multiplex immunofluorescence workflow and deep-learning analysis enabled the identification of immune niches associated with therapeutic response, and how this approach could be expanded across cancer types.
Designed for a global audience of translational researchers and clinicians, the session will feature two live broadcasts with Q&A to accommodate participants across regions.
By the end of this webinar, participants will:
-
Understand how multiplex imaging and AI-powered spatial analysis can identify predictive biomarkers and the spatial features that inform treatment selection in melanoma and other cancers.
-
Explore how spatial biology enhances translational research by revealing immune cell interactions that drive therapy response or resistance.
-
Recognize how emerging analytical workflows can bridge discovery and clinical practice, accelerating the adoption of precision oncology worldwide.
The webinar is expected to run for about 60 minutes.
Paolo Ascierto National Tumor Institute Naples, Italy
Ettai Markovits Nucleai Tel Aviv, Israel
Antonio Sorrentino Lunaphore Technologies Tolochenaz, Switzerland
Erika Berg Science/AAAS Washington, DC